← European Medicine Shortage Tracker · all medicines

Levosimendan shortage — availability across Europe

Availability information only — Mobi Doctor doesn't sell medicines; check with a pharmacy.

MEDICALLY REVIEWED
Dr. Chrysoula I. Liakou MD, PhD
Internal Medicine Specialist
Cancer Immunology Researcher
Reviewed 30 July 2026 · next review due 30 January 2027

Levosimendan currently has availability issues reported in 3 European registers: Spain, Greece, Sweden.

Shortage  ATC C01CX08 · also listed as: LEVOSIMENDAN · data refreshed 14 September 2026

Key facts

As of 14 September 2026, 3 of the 9 tracked registers list current availability issues for Levosimendan, covering 7 affected product presentations. The longest-running open report was filed in Sweden on 2023-11-29 and has now been open for about 34 months. The furthest expected-resolution date currently on file is 2027-01-31; the earliest is 2026-12-01. Notably, 2 reports have already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. The issue spread across registers over time rather than at once: Sweden reported first (2023-11-29), with Greece following roughly 29 months later — a pattern typical of supply problems cascading between national markets. Registers in Spain, Greece, Sweden indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Levosimendan is coded C01CX08 — a medicine acting on the cardiovascular system — so clinically related products appear under “Related medicines” below.

WhereStatus & productsSinceExpected end Reason / alternativesSource
🇪🇸 SpainShortage
LEVOSIMENDAN ACCORD 2,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 vial de 5 ml
+ 1 more products
LEVOSIMENDAN ZENTIVA 2,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 vial de 5 ml
2025-06-252026-12-30Existen otros medicamentos con el mismo principio activo y misma vía.
Alternatives: Existe/n otro/s medicamento/s con el mismo principio activo y para la misma vía de administración.
register ↗
🇬🇷 GreeceLimited availability
1 VIAL X 5ML
2026-04-172026-12-01WIN MEDICA A.E., ΕΛΛΑΔΑ διαδικασία Εναλλακτικά άλλο σκεύασμα της ίδιας
Alternatives: APREDONAV F.C.TAB 5MG/TAB BTx56 TABS (σε BLISTER Εναλλακτικά άλλα σκευάσματα της ίδιας δρα
register ↗
🇸🇪 SwedenShortage
Levosimendan Amdipharm 2,5 mg/ml Koncentrat till infusionsvätska, lösning
+ 3 more products
Levosimendan EQL Pharma 2,5 mg/ml Koncentrat till infusionsvätska, lösning
Levosimendan Kalceks 2,5 mg/ml Koncentrat till infusionsvätska, lösning
Simdax 2,5 mg/ml Koncentrat till infusionsvätska, lösning
2023-11-292027-01-31
Alternatives: Alternative(s) available — see the national register.
register ↗

New register reports per month

2024-08: 12024-09: 02024-10: 02024-11: 02024-12: 02025-01: 02025-02: 02025-03: 02025-04: 02025-05: 02025-06: 12025-07: 12025-08: 02025-09: 02025-10: 12025-11: 02025-12: 02026-01: 02026-02: 02026-03: 02026-04: 12026-05: 02026-06: 12024-082026-06

Full report history (7 register entries)

Every individual register entry for Levosimendan in the tracked sources, newest first — including resolved and discontinued reports.

Reg.ProductStatusReportedExpected endStated reason
🇸🇪 SESimdax 2,5 mg/ml Koncentrat till infusionsvätska, lösningShortage2026-06-222026-07-27
🇬🇷 GR1 VIAL X 5MLLimited availability2026-04-172026-12-01WIN MEDICA A.E., ΕΛΛΑΔΑ διαδικασία Εναλλακτικά άλλο σκεύασμα
🇪🇸 ESLEVOSIMENDAN ACCORD 2,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONShortage2025-10-082026-12-30Existen otros medicamentos con el mismo principio activo y m
🇸🇪 SELevosimendan Amdipharm 2,5 mg/ml Koncentrat till infusionsvätska, lösnShortage2025-07-232026-08-31
🇪🇸 ESLEVOSIMENDAN ZENTIVA 2,5 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIOShortage2025-06-25Existen otros medicamentos con el mismo principio activo y m
🇸🇪 SELevosimendan EQL Pharma 2,5 mg/ml Koncentrat till infusionsvätska, lösShortage2024-08-072027-01-31
🇸🇪 SELevosimendan Kalceks 2,5 mg/ml Koncentrat till infusionsvätska, lösninShortage2023-11-292026-12-25

Frequently asked

Is Levosimendan currently in shortage in Europe?

Yes. As of 14 September 2026, availability issues are reported in: Spain, Greece, Sweden. Availability is national — a shortage in one country does not mean it is short everywhere.

When is the Levosimendan shortage expected to end?

Agency prognoses on file range from 2026-12-01 to 2027-01-31. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.

Are there alternatives to Levosimendan?

7 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.

Where does this Levosimendan availability data come from?

Directly from the official medicines-agency registers that list Levosimendan: AEMPS CIMA (Spain), EOF limited-availability list (Greece), Läkemedelsverket (Sweden). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.

Related medicines (same ATC class)

Embed this tracker

Pharmacies, patient sites and newsrooms are welcome to embed the live status of Levosimendan — free, with attribution. Copy this snippet:

<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/levosimendan/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Levosimendan availability in Europe"></iframe>
<p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/levosimendan/">Levosimendan shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>
Cite: “Levosimendan: availability status across 3 European registers — European Medicine Shortage Tracker (MobiDoctor), 14 September 2026.” Link this page and the agency record. Statuses come from the linked official registers and can change daily.